Cytek Biosciences Inc (CTKB)
Debt-to-assets ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total assets | US$ in thousands | 499,500 | 494,457 | 519,476 | 463,700 | 219,979 |
Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $499,500K
= 0.00
The debt-to-assets ratio of Cytek Biosciences Inc has consistently been at 0.00 for the years 2020, 2021, 2022, 2023, and 2024. This indicates that the company has no debt in relation to its total assets during these years. A debt-to-assets ratio of 0.00 signifies that the company's assets are entirely financed by equity rather than debt, showing a strong financial position in terms of solvency and risk management.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-assets ratio
Cytek Biosciences Inc
CTKB
0.00
Avantor Inc
AVTR
0.27
Bio-Rad Laboratories Inc
BIO
0.00
Bruker Corporation
BRKR
0.36
Illumina Inc
ILMN
0.24
Mettler-Toledo International Inc
MTD
0.57
Revvity Inc.
RVTY
0.25
Waters Corporation
WAT
0.36